Introduction
============

Allogenic hematopoietic stem cell transplantation (HSCT) is the predominant treatment used to cure malignant and non-malignant hematological disorders. The number of HSCTs conducted has increased due to an overall improvement in the safety of the procedure resulting from reduced-intensity conditioning regimens, and the availability of new donor sources, available in the national registries ([@b1-mmr-14-04-2967],[@b2-mmr-14-04-2967]).

Reduced-intensity conditioning is widely used to avoid the complications of myeloablative conditioning to prepare for HSCT in the adult population. However, this procedure is associated with a high risk of complications that may result in graft loss. To prevent this, it is important to monitor chimerism for early intervention ([@b3-mmr-14-04-2967]). Evaluation of chimerism status at regular intervals is useful to prevent risk of early graft rejection and relapse in patients suffering from malignant diseases. Quantification of the chimerism percentage is also a potential marker of minimal residual disease (MRD) for patients without suitable MRD markers and it provides useful information on graft vs. host disease and graft vs. tumor effects ([@b4-mmr-14-04-2967]--[@b6-mmr-14-04-2967]).

Chimerism analysis is a tool that allows to determination of the genotypic origin of post-transplantation hematopoiesis. Subsequent to HSCT, a patient presenting with 100.0% donor-origin cells during follow up is considered to have the status of complete chimerism (CC), patients in which the donor- and recipient-origin cells coexist have the status of mixed chimerism (MC) ([@b7-mmr-14-04-2967]). Informative genetic markers are used to discriminate between recipient and donor genomes in order to detect the chimerism status ([@b8-mmr-14-04-2967]).

At present, different approaches based on polymerase chain reaction (PCR) amplification of polymorphic DNA sequences (short tandem repeat, STR; single nucleotide polymorphism, SNP; and insertion/deletion, INDEL) are used for chimerism analysis. In the vast majority of laboratories, semi-quantitative fluorescent PCR of STRs is the procedure of choice for diagnostic purposes. The key advantage offered by this method is the highly polymorphic nature of the STR markers, which allow for a high probability of two-genome discrimination. Laboratories currently use different commercial multiplex kits for forensic identifications or in house assays, however have formed consortiums to standardize procedures and set guidelines for the correct interpretation of results, in order to improve this intrinsically semi-quantitative platform with a sensitivity of 1.0--3.0% ([@b9-mmr-14-04-2967]).

Next generation sequencing (NGS) technologies are an innovation in human and animal genomics research, as they are capable of producing 100-fold more data than the most powerful Sanger based capillary sequencers; thus enabling researchers to investigate the large number of queries that remain to addressed ([@b10-mmr-14-04-2967]).

NGS generates hundreds of giga-bases of nucleotide sequences per instrument run and produces this data at a lower cost, thus motivating researchers to use NGS for various purposes: To identify rare variations on the whole genome or on a target sequence, to analyze transcriptome profiling of cells, tissues and organisms and to identify epigenetic markers for disease diagnosis. Progress in the optimization of procedures, in addition to further reduction of costs, are the key factors that will lead to a more extensive uptake of this technique in diagnosis and for practical clinical applications.

NGS provides qualitative and quantitative data. Quantitative data depends on the depth of sequence data collected on each sample and on the quality of the target to expose. For samples with a lower abundance target, many more sequence reads are required to achieve accurate quantification ([@b11-mmr-14-04-2967]). A previous study demonstrated that NGS exhibits sensitivity comparable to that of quantitative PCR (qPCR) in the evaluation of MRD in B cell disorders ([@b12-mmr-14-04-2967]).

In the present study, an Ion AmpliSeq custom chimerism (ACCh) panel and a custom bioinformatic pipeline was created for chimerism quantification by NGS. The first aim was to detect the existence of cells of two origins in chimera samples and then to evaluate the capability of NGS to determine the percentage of the recipient cells.

Materials and methods
=====================

DNA sample preparation
----------------------

The Ethics Committee of the Institute for Maternal and Child Health, IRCCS \'Burlo Garofolo\' approved the present study (approval number: Prot. 18/2015, Cl. M/11). Written informed consent was obtained from all the participants.

Total peripheral blood was collected from 10 volunteer donors (V01-V10; 4 males and 6 females) with ages ranging from 20--50 years, and from 2 pediatric patients that underwent allogeneic HSCT (pR1, male, 5 years; and pR2, male, 12 years) and their donors (pD1, male, 9 years; and pD2, female, 25 years; [Table I](#tI-mmr-14-04-2967){ref-type="table"}). Written informed consent was obtained from all the participants.

All DNA samples were isolated using the QIAamp DNA Blood kit according to manufacturer\'s protocol (Qiagen GmbH, Hilden, Germany). The DNA status was evaluated using the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and the Qubit dsDNA HS Assay kit and the Qubit fluorometer (Thermo Fisher Scientific, Inc.). A DNA stock solution was prepared for all DNA samples at 20.0 ng/*μ*l.

DNA samples from the 10 volunteer donors were randomly paired. A total of 5 artificial chimeric DNA mixtures, as the donor/recipient chimera, were created by diluting DNA with its paired DNA at several percentages of the first DNA for each artificial DNA mixture (aCh).

Ion AmpliSeq custom chimerism panel design
------------------------------------------

A multi phase strategy was employed to evaluate the main characteristics of the ACCh panel: i) The panel average heterozygosity was assessed around 0.5 for the European population (HapMap Phase 3 CEU population); ii) two SNPs per somatic chromosome, termed \'main SNPs\' (mSNPs), were selected and located in two different regions of the same chromosome; iii) the amplicon composition was evaluated according to the following requirements: a) GC percentage ranging between 40.0 and 60.0%; b) presence of one mSNP inside each amplicon; c) mSNP location preferably in the centre of the amplicon; d) absence of INDEL SNPs; e) absence of homopolymers and potential homopolymer generation from SNP variants and their flanking regions; f) absence of flanking SNPs to the mSNPs.

In total, 44 single-nucleotide, biallelic, polymorphisms were selected from the NCBI dbSNPs database (<http://www.ncbi.nlm.nih.gov/SNP/>, build 138, last database update 28.03.2014; [Table II](#tII-mmr-14-04-2967){ref-type="table"}). A total of 4 base sequences including mSNPs were used as target regions for primer design. The primer pool, intended for DNA library construction through multiplex PCR, was defined by Ion AmpliSeq Designer software, version 3.0.1 (Thermo Fisher Scientific, Inc.). A single-tube, 44 primer pair pool was purchased from Life Technologies (Thermo Fisher Scientific, Inc.).

Ion torrent library preparation and sequencing
----------------------------------------------

DNA sample library preparation was performed according to the AmpliSeq Library Preparation protocol (Life Technologies; Thermo Fisher Scientific, Inc.). For each DNA sample, a library was constructed using 10.0 ng genomic DNA through the Ion AmpliSeq Library kit, version 2.0. Subsequently, according to the library preparation protocol, each DNA library was indexed using the Ion Xpress Barcode Adapters kit (Thermo Fisher Scientific, Inc.) and was purified using AMPure XP magnetic beads (Beckman Coulter, Inc., Brea, CA, USA). Each DNA library was then quantified by qPCR using the thermo-cycler 7900HT Fast Real-Time PCR system with the Ion Library TQMN Quantification kit (Thermo Fisher Scientific, Inc.). Template Ion Sphere Particles were arranged using the Ion Personal Genome Machine (PGM) Template OT2 200 kit (Thermo Fisher Scientific, Inc.) and a single end 200 base-read sequencing run was conducted using the Ion Torrent PGM system. Libraries were pooled at 8 pM using the following rates: Donor/recipient, 1:1; and chimera/chimera, 1:1. The recipient/chimera rate was fixed at 1:40 in order to obtain an average coverage of the above libraries around 250X:10,000X. Library pools were sequenced on ion 314 and 316 chip ([Table III](#tIII-mmr-14-04-2967){ref-type="table"}).

Hotspot panel bed file
----------------------

A hotspot panel bed file was created using the UCSC Genome Browser (<https://genome.ucsc.edu>). All SNPs located in the central region of each amplicon were included (NCBI dbSNPs build 138; \'Common SNPs\' =286). All the INDELs present across the amplicons, and the SNPs near the 5′ and 3′ ends of the amplicons were excluded from the file. All the above 44 selected SNPs were marked as \'mSNP\' and the SNPs belonging to the same amplicon were indexed with the same chromosome/amplicon ID number. Finally, a hotspot panel bed file was created: \'HP286SNPs\'.

Genotyping and quantification
-----------------------------

Genotyping of all DNA was performed automatically, together with the quantification of all the chimeras, using a custom bioinformatics tool. The code of our tool was written using the Shiny package in R, a web framework to build interactive web applications (<https://cran.r-project.org/web/packages/shiny/index.html>). A functional diagram of the code is presented in [Fig. 1](#f1-mmr-14-04-2967){ref-type="fig"} and the full code is available on request. The code is based on dependencies of the Bioconductor package that must be pre-installed for proper tool functionality.

The custom tool requires as input the sequencing bam files of \'Donor\', \' Recipient\' and \'Chimeric\' patient. Briefly, it uses readGAlignments and pileLettersAt functions, from the GenomicAlignments package ([@b13-mmr-14-04-2967]), to read bam files and extracts the letters/nucleotides into a set of individual genomic positions defined from the bed file. Thresholds for \'Donor\' and \'Recipient\', homozygous and heterozygous genotyping calls, are settled in base counts frequency ranges of 90.0--100.0% and 30.0--60.0%, respectively. Genotyping calls not included in the thresholds ranges were excluded as unreliable; users can modify the thresholds according to their needs from the user interface. Genotypes from each library were crosschecked to select only SNPs comparable in all conditions. Selected SNPs from donors and recipients were labelled as informative recipient alleles (IRA) according to the following schema: Donor homozygous and recipient heterozygous \[Donor (AA) and Recipient (Aa); Donor (aa) and Recipient (Aa)\]; donor and recipient homozygous for different alleles \[Donor (AA) and Recipient (aa); Donor (aa) and Recipient (AA)\].

Only the IRA SNPs tagged as informative were used to calculate the chimera\'s donor:recipient ratio as median of the allele frequency ratio, while standard error was used to calculate confidence intervals of prediction at 95.0%.

To cross validate the tool, genotyping of all donor and recipient samples was also performed manually obtaining the variant data from the Ion Torrent plugin Variant Caller, version 4.4 using the \'Generic-PGM-Germ Line-Low Stringency\' configuration coupled by the HP286SNPs hotspot bed file.

Microsatellite analysis and patient data validation
---------------------------------------------------

Multiplex PCR amplification of V01-V10 and aCh~1--13~ samples, in addition to the patient samples pD2, pR2 and pCh~1--6~, was performed according to the manufacturer\'s instructions of the AmpFlSTR Identifiler Plus PCR Amplification kit (Thermo Fisher Scientific, Inc.). Amplicons were resolved on a Genetic Analyzer 3130 and analyzed with GeneMapper software, version 4.1 (Life Technologies; Thermo Fisher Scientific, Inc.).

Patient samples (pCh~1--6~) were also analyzed by qPCR (data not shown), as previously investigated by Bai *et al* ([@b14-mmr-14-04-2967]). This analysis was performed as an additional validation method of NGS data, where a discrepancy between NGS and STR data was present.

Results
=======

Ion chips and ACCh panel performance
------------------------------------

A total of 7 library pools were loaded and sequenced on ion chip 314. Each pool was comprised of one donor, one recipient and one chimera. In addition, three additional pools were run on ion 316 chip ([Table III](#tIII-mmr-14-04-2967){ref-type="table"}). The mean values of performance of the 10 runs and of all samples are summarized in [Table IV](#tIV-mmr-14-04-2967){ref-type="table"}.

NGS genotyping performances using the ACCh panel
------------------------------------------------

A total of 14 DNA samples were genotyped on Ion Torrent PGM using the ACCh panel with the HP286SNPs bed file. Regarding the mSNPs, the Variant Caller output identified that 2 mSNPs (rs121893 and rs12612347) were assigned as \'No Call\' in over 50.0% of the genotyping runs due to low quality. The remaining 42 mSNPs were successfully genotyped. Concerning the remaining 242 SNPs, 27 SNPs were assigned as \'No Call\', with an average of 10 SNPs per patient. The call of these SNPs failed in two Variant Caller filtering steps: \'Maximum common signal shift\' and \'minimum coverage on either strand\'.

Genotyping of all samples was additionally performed using our tool with the HP286SNPs bed file ([Table V](#tV-mmr-14-04-2967){ref-type="table"}). To identify the IRAs, the data of the donor was compared with the recipient using the tool and manually cross-validated with the Variant Caller genotypes. Inside the genotyping calls of 242 SNPs, a small bias was present between these 2 tools; this is due to the high conserved filters of variant caller, dedicated predominantly for standard sequencing applications, and due to the absence of these filters in our custom tool.

NGS linearity, detection limit and accuracy with the ACCh panel
---------------------------------------------------------------

In order to test the linearity of Ion Torrent PGM with the ACCh panel in a fixed detection range (0.5--100.0%), a series of DNA mixtures was developed, diluting a DNA with its paired DNA at several percentages of the original. In order to increase the genetic marker variability in addition to the biological variability, a total of 12 artificial chimeras (aCh~1--12~) were prepared from 5 different DNA pairs. Finally a pure DNA (V09) was run as 100.0% DNA (aCh~13~). Subsequent to Ion Torrent sequencing, using the custom tool, quantitative data for all IRAs of each artificial chimera were obtained.

In addition, to increase the putative points in the dynamic range, the informative alleles of both DNA in the chimeras aCh~12~ (40.0% of V09 and 60.0% of V10) and aCh~11~ (20.0% of V07 and 80.0% of V08) were calculated and quantified.

Least-squares analysis of the above putative points identified a clear linearity (R^2^=0.999; Y=1.008X-0.005) between NGS and the reference values ([Fig. 2](#f2-mmr-14-04-2967){ref-type="fig"}).

Analyzing the artificial chimeras aCh~6--13~ by capillary electrophoresis using the STRs markers, chimerism ranging from 4.0--100.0% was detected. Least-squares analysis identified a clear linearity (R^2^=0.999; Y=1.012X-0.009) between NGS and STRs values ([Fig. 3](#f3-mmr-14-04-2967){ref-type="fig"}).

In addition, the background of Ion Torrent generated by the ACCh panel was estimated. In this case, the custom tool was used, considering the \'donor\' samples as chimera. The average background value at each SNP was estimated at 0.3% (range, 0.0--0.8%) and with a 95.0% confidence interval between 0.1 and 0.5%. Considering the background values and the reported literature on the error rates at each base of NGS technologies (range from 0.04--1.0%) ([@b15-mmr-14-04-2967]), the detection limit of the NGS protocol with the ACCh panel was set at 1.0%, although an artificial chimera was detected at 0.5%.

Finally, considering that the method determined each chimera, calculating the average value of all IRA, the average standard error was used as an indirect marker of accuracy, using the data of all artificial chimeras ranging from 1.0--99.0% (excluding 0.5 and 100.0%). For the dynamic range of 1.0--20.0% of chimeras, the average standard error was calculated at 0.3% with a deviation at 0.2%. For higher values of chimeras, up to 99.0%, the standard error increased up to 1.8% with a maximum deviation at 2.0%.

Patient chimerism evaluation on the NGS platform
------------------------------------------------

Considering the linearity between NGS and reference values and between NGS and STR values using the standard NGS workflow and the custom tool, our workflow was tested in 6 samples of the same patient (pCh~1--6~) in which the chimerism quantification report, previously performed by microsatellite analysis at different times in an external laboratory (Department of Molecular Medicine, University of Padova, Padova, Italy), presented at least one CC between two MCs ([Table I](#tI-mmr-14-04-2967){ref-type="table"}).

NGS analysis detected a mixed chimerism in all samples (pCh~1~, pCh~2~, pCh~3~, pCh~4~, pCh~5~ and pCh~6~) while the microsatellite analysis only in 4 of them (pCh~1~, pCh~3~, pCh~4~ and pCh~5~). For these 4 MC samples, the percentage of predicted chimerism was equal between the 2 methods of analysis ([Fig. 4](#f4-mmr-14-04-2967){ref-type="fig"}). In regard to the pCh~2~ and pCh~6~ samples, NGS analysis evaluated a mixed chimerism at 3.0 and 2.0%, respectively ([Fig. 4](#f4-mmr-14-04-2967){ref-type="fig"}).

To confirm the obtained NGS data for the pCh~2~ and pCh~6~ samples, the NGS analysis was repeated, and qPCR was additionally perfomed in all patient samples. The results of qPCR analysis were in agreement with that of the NGS and microsatellite data for the pCh~1~, pCh~3~, pCh~4~ and pCh~5~, and confirmed the NGS data for the pCh~2~ and pCh~6~ samples.

Discussion
==========

NGS technologies have revolutionized the field of genomics, and its application has been extended to different fields such as clinical diagnostics and forensic science ([@b15-mmr-14-04-2967]--[@b17-mmr-14-04-2967]). As a result of the continuous development of NGS, several applications previously performed on Sanger sequencing with capillary electrophoresis have been transferred onto the NGS platform, enabling fast and cost-effective generation sequence data with high resolution and accuracy. For this reason, different panels are being developed for the sequencing of genetic mutations involved in human diseases (e.g. MiSeqDx Cystic Fibrosis Clinical Sequencing Assay; Illumina, Inc., San Diego, CA, USA) or in cancer (Ion AmpliSeq BRCA1 and BRCA2 Panel; Life Technologies; Thermo Fisher Scientific, Inc.).

In the field of chimerism quantification by NGS platforms, Debeljak *et al* ([@b18-mmr-14-04-2967]) reported an innovative and well performed study, using haplotype counting. In addition, Kim *et al* ([@b19-mmr-14-04-2967]) briefly reported a relative quantification analysis of SNP markers by NGS in one human bone marrow chimerism sample. However, the study by Kim *et al* ([@b19-mmr-14-04-2967]) was conducted in a 4.9% chimerism sample without any detail concerning the limit of detection, the technical error or additional important technical information and validation data of NGS application in chimerism quantification.

In the present study, a full workflow was designed, and the proposed protocols and a bioinformatics tool were tested for chimerism quantification by NGS. A 44-amplicon custom chimerism panel based on Ion AmpliSeq technology was designed, and in addition a bioinformatics tool dedicated to the genotyping and quantification of NGS data was coded. These resources were created in order to provide a novel tool for the evaluation of the chimerism following allogenic HSCT, thus potentially increasing the number of clinical analyses supported on NGS platforms.

The ACCh proposed panel is composed of 44 amplicons, containing 44 selected mSNPs, of which 2 mSNPs are located in different regions of each somatic chromosome. It is suggested that the different mSNP locations in all somatic chromosome may be useful to avoid predominantly false negatives results caused by chromosomal deletions characteristic of certain malignancies ([@b20-mmr-14-04-2967]). In addition, the bed file uploaded in the custom tool, containing all targeted SNPs, can be modified in order to exclude the SNPs present in chromosome target regions subjected to deletions in a specific patient.

The panel average heterozygosity was assessed around 0.5 for the European population in order to obtain different informative markers for each transplanting pair, for a more precise and robust quantification. The theoretical panel informativity for unrelated donor:recipient values, calculated according to the data present on the NCBI dbSNPs database, was estimated to be approximately 16/42 mSNPs, while for siblings the informativity was estimated at 50.0% (approximately 8/42 mSNPs). In order to increase the informativity of the ACCh panel, an additional 242 selected SNPs present in the targeted regions were included in the bed file. This addition of SNPs experimentally increased the average informativity ([Table V](#tV-mmr-14-04-2967){ref-type="table"}).

The ACCh panel reached the limit of detection on the Ion Torrent PGM platform of 0.5%, however, this was updated to the conservative value of 1.0% for two reasons: i) The Ion Torrent error is defined to be between 0.04 and 1.0% ([@b21-mmr-14-04-2967]); and ii) the background of the ACCh panel, based on the IRA data of our experiments, ranges between 0.1 and 0.5%.

Regarding the timing of chimerism analysis, the UK NEQAS Consortium has recommended that results should be assessed in 5 working days from the reception of the sample and in 3 working days for urgent requests ([@b6-mmr-14-04-2967]). The protocol suggested in the current study is feasible in 2 days; the first day for library preparation and quantification and the second for template preparation, run sequence and data analysis. In addition, due to the fact the ACCh protocol suggested in the current study does not present any differences from the standard AmpliSeq Library Preparation and Ion Torrent PGM Run Sequence protocols, it is possible to introduce it to a standard manual library preparation workflow or in a library preparation workstation.

Considering the AmpliSeq library construction protocol (based on multiplex PCR) from Life Technologies (Thermo Fisher Scientific, Inc.), the same concept could be tested on additional NGS platforms, such as Illumina or Roche, according to their library preparation protocols. Concerning the custom bioinformatics tool, any bam and bai file coupled by a bed file, generated from any platform could be used.

At present, the cost of NGS analysis, compared with microsatellite methods, remains high, however considering the continuously reducing cost per NGS run, an NGS-based method for chimerism quantification could be evaluated in the future for its adoption in laboratories with a high volume of activity, and with NGS platforms already in use for other purposes. Although the present study reported a clear correlation between NGS and STR methods and identifed important technical details, further experimental replications are required in order for the NGS protocol to be validated for future laboratory use.

The current study was supported by a grant from the Institute of Maternal and Child Health-IRCCS \'Burlo Garofolo\' (grant no. RC 16-2014). The authors would like to thank Dr Erika Ferrari for assistance with SNP data crosschecking.

![Code functional diagram. All output next generation sequencing files and reference files were uploaded to the custom pipeline. A quality control filtering step per target base was performed and the genotypes for donor and recipient samples were defined. Finally, subsequent to identification of the informative recipient allele, statistical analysis was conducted to determined the chimerism percentage. A, adenosine; C, cytosine; T, thymine; G, guanine; SNP, single nucleotide polymorphism; IRA, informative recipient allele.](MMR-14-04-2967-g00){#f1-mmr-14-04-2967}

![Linearity of Ion AmpliSeq custom chimerism panel: NGS against references values. A series of artificial chimeras, ranging between 0.5--100.0%, were quantified by NGS and plotted against their reference values. NGS, next generation sequencing.](MMR-14-04-2967-g01){#f2-mmr-14-04-2967}

![Linearity of Ion AmpliSeq custom chimerism panel: NGS against microsatellite values. A series of artificial chimeras were quantified by a standard microsatellite method (short tandem repeats) and the data were plotted compared to the NGS values. The chimeras ranging between 0.5--2.5% were not able to be quantified by short tandem repeats due to the detection limit of the informative markers. NGS, next generation sequencing.](MMR-14-04-2967-g02){#f3-mmr-14-04-2967}

![Patient sample evaluation with NGS and microsatellites (STRs) methods. Samples (n=6) taken from the same patient at different time points, ranging from 1--10 months subsequent to HSCT, were compared using the two methods. At +2 (pCh~2~) and +10 (pCh~6~) months, the STRs method was not able to detect the recipient DNA. NGS, next generation sequencing; STRs, short tandem repeats; HSCT, hematopoietic stem cell transplantation.](MMR-14-04-2967-g03){#f4-mmr-14-04-2967}

###### 

List of the patient DNA samples used in the present study.

  DNA ID   Chimera ID   Chimera information                                             Notes                                                                 
  -------- ------------ --------------------------------------------------------------- --------------------------------------------------------------------- ----------------------
  pD1      pR1          Samples used to evaluate panel informativity in consanguinity   Brothers, pre-HSCT                                                    
  pD2      pR2          pCh~1~                                                          MC by STR-CE analysis[a](#tfn1-mmr-14-04-2967){ref-type="table-fn"}   +1 month post-HSCT
  pD2      pR2          pCh~2~                                                          CC by STR-CE analysis                                                 +2 months post-HSCT
  pD2      pR2          pCh~3~                                                          MC by STR-CE analysis                                                 +3 months post-HSCT
  pD2      pR2          pCh~4~                                                          MC by STR-CE analysis                                                 +4 months post-HSCT
  pD2      pR2          pCh~5~                                                          MC by STR-CE analysis                                                 +6 months post-HSCT
  pD2      pR2          pCh~6~                                                          CC by STR-CE analysis                                                 +10 months post-HSCT

Chimerism evaluation of all patient samples (pCh~1--6~) was performed by STR-CE analysis in an external laboratory (Department of Molecular Medicine, University of Padova, Padova, Italy). HSCT, hematopoietic stem cell transplantation; MC, mixed chimerism; CC, complete chimerism; STR-CE, short tandem repeat capillary electrophoresis.

###### 

List of all main SNPs included in the Ion AmpliSeq custom chimerism panel.

  SNP ID       Genome position     Alleles   European heterozygosity   Informativity of recipient allele[a](#tfn2-mmr-14-04-2967){ref-type="table-fn"} %
  ------------ ------------------- --------- ------------------------- -----------------------------------------------------------------------------------
  rs12070036   chr1:g.227819514    A/G       0.407                     41
  rs1234315    chr1:g.173178463    C/T       0.513                     37
  rs10496711   chr2:g.134516742    C/G       0.407                     40
  rs12612347   chr2:g.219057338    A/G       0.442                     40
  rs1984630    chr3:g.134414219    G/T       0.522                     36
  rs9831477    chr3:g.30693522     A/T       0.483                     38
  rs10033900   chr4:g.110659067    C/T       0.496                     37
  rs5335       chr4:g.148463840    C/G       0.492                     37
  rs983889     chr5:g.15555486     A/C       0.487                     38
  rs10038113   chr5:g.25902342     C/T       0.469                     38
  rs552655     chr6:g.13370488     A/G       0.504                     37
  rs2077163    chr6:g.33636907     C/T       0.460                     39
  rs39395      chr7:g.103489729    A/G       0.425                     40
  rs2270188    chr7:g.116140524    G/T       0.496                     38
  rs10505477   chr8:g.128407443    C/T       0.531                     36
  rs532841     chr8:g.12957475     C/T       0.549                     35
  rs2297313    chr9:g.91669362     A/G       0.960                     37
  rs424539     chr9:g.14442595     C/G       0.467                     38
  rs1561570    chr10:g.13155726    C/T       0.522                     36
  rs619824     chr10:g.104581288   G/T       0.407                     41
  rs198464     chr11:g.61521621    C/T       0.504                     37
  rs178503     chr11:g.44082931    A/G       0.442                     40
  rs1126758    chr12:g.103248924   A/G       0.416                     40
  rs8608       chr12:g.53294381    A/G       0.522                     36
  rs1061472    chr13:g.52524488    A/G       0.504                     37
  rs504544     chr13:g.19735891    A/T       0.508                     37
  rs10143250   chr14:g.104723433   C/T       0.434                     39
  rs1957779    chr14:g.63669647    C/T       0.449                     39
  rs634990     chr15:g.35006073    A/G       0.492                     38
  rs2117215    chr15:g.94879684    C/T       0.603                     32
  rs121893     chr16:g.66183995    C/T       0.414                     39
  rs2191125    chr16:g.7720923     T/C       0.550                     34
  rs6808       chr17:g.62400575    C/G       0.450                     39
  rs744166     chr17:g.40514201    T/C       0.441                     40
  rs620898     chr18:g.48509148    A/T       0.467                     38
  rs633265     chr18:g.57831468    A/C       0.496                     37
  rs108295     chr19:g.34224816    A/G       0.496                     37
  rs892086     chr19:g.10837677    C/T       0.451                     39
  rs753381     chr20:g.39797465    T/C       0.451                     39
  rs715147     chr20:g.50055350    G/A       0.367                     43
  rs225436     chr21:g.43729034    A/G       0.517                     36
  rs8128316    chr21:g.35721560    C/T       0.542                     35
  rs4444       chr22:g.31205334    A/G       0.483                     38
  rs132985     chr22:g.38563471    C/T       0.517                     37

In order to calculate the probability (informativity) to identify an informative recipient allele in a casual donor/recipient pair, the single values of probability of each genotype combination that carry an informative recipient allele were added as follows: Donor homozygous and recipient heterozygous \[Donor (AA) and Recipient (Aa); Donor (aa) and Recipient (Aa)\]; donor and recipient homozygous but for different alleles \[Donor (AA) and Recipient (aa); Donor (aa) and Recipient (AA)\]. SNP, single nucleotide polymorphism; A, adenine; G, guanine; C, cytosine; T, thymine.

###### 

List of the library pools sequenced by next generation sequencing.

  DNA ID     Chimera ID           Chimera notes                                                                                          Ion chip
  ---------- -------------------- ------------------------------------------------------------------------------------------------------ ----------
  V01, V02   aCh~1~               Chimera: 1.0% of V01; 99.0% of V02                                                                     314
  V03, V04   aCh~2~               Chimera: 1.25% of V03; 98.75% of V04                                                                   314
  V03, V04   aCh~3~               Chimera: 2.5% of V03; 97.5% of V04                                                                     314
  V05, V06   aCh~4~               Chimera: 5.0% of V05; 95.0% of V06                                                                     314
  V05, V06   aCh~5~               Chimera: 10.0% of V05; 90.0% of V06                                                                    314
  V07, V08   aCh~6,7,8,9,10,11~   Chimeras: 0.5%, 1.0%, 4.0%, 8.0%, 12.0%, 20.0% of V07; 99.5%, 99.0%, 96.0%, 92.0%, 88%, 80.0% of V08   316
  V09, V10   aCh~12,13~           Chimeras: 40.0% of V09 and 100% of V09; 60.0% of V10 and 0.0% of V10                                   316
  pD2, pR2   pCh~1,2,3,4,5,6~     Chimeras: MC, CC, MC, MC, MC, CC of pR2[a](#tfn3-mmr-14-04-2967){ref-type="table-fn"}                  316
  pD2, pR2   pCh~2~               Technical replication                                                                                  314
  pD1, pR1   pCh~6~               Technical replication                                                                                  314

All patient samples were previously analyzed by short tandem repeat capillary electrophoresis in an external laboratory (Department of Molecular Medicine, University of Padova, Padova, Italy).

###### 

In-house Ion Torrent Personal Genome Machine analysis observed average performances using the Ion AmpliSeq custom chimerism panel on ion 314 and 316 chips.

  A, In-house observed performance   Ion 314 chip   Ion 316 chip
  ---------------------------------- -------------- --------------
  Ion sphere particles loading       84.3%          70.0%
  Total bases (Mb)                   105.1          677.0
  Total reads                        533,535        3,474,065
  Reads on-target                    99.7%          99.3%
  Panel uniformity                   97.6%          96.0%

  B, Coverage performance                          Ion 314 chip                   Ion 316 chip
  ------------------------------------------------ ------------------------------ -------------------------------
  Chimera samples - amplicons over 2,500X          43/44 range 4,069X--23,944X)   43/44 (range 4,777X--28,314X)
  Donor & recipient samples - amplicons over 50X   44/44 (range 105X--952X)       44/44 (range 75X--2328X)

###### 

List of the number of IRAs identified in each DNA pair using the custom pipeline.

  DNA pair \'Donor\'/\'Recipient\'   Custom pipeline   IRA genotypes   Total IRAs (%)[a](#tfn4-mmr-14-04-2967){ref-type="table-fn"}       
  ---------------------------------- ----------------- --------------- -------------------------------------------------------------- --- ---------
  V01/V02                            15                3               10                                                             8   18 (43)
  V03/V04                            18                4               19                                                             3   22 (52)
  V05/V06                            14                4               14                                                             4   18 (43)
  V07/V08                            13                5               10                                                             8   18 (43)
  V09/V10                            8                 3               8                                                              3   11 (26)
  V02/V01                            15                5               12                                                             8   20 (48)
  V04/V03                            7                 2               6                                                              3   9 (21)
  V06/V05                            14                2               12                                                             4   16 (38)
  V08/V07                            16                4               12                                                             8   20 (48)
  V10/V09                            19                3               19                                                             3   22 (52)
  pD1/pR1                            9                 2               9                                                              2   11 (26)
  pD2/pR2                            17                4               18                                                             3   21 (50)

The percentage of each IRA was calculated on 42--44 amplicons, due to the low quality of the remaining two, considering that each amplicon could contain at least one potential IRA. IRA, informative recipient allele; mSNP, main single nucleotide polymorphism.

[^1]: Contributed equally
